 Zynerba Pharmaceuticals Inc has announced the initiation of a pivotal, multinational randomized, double-blind, placebo-controlled, multiple-center RECONNECT Phase 3 trial to evaluate the efficacy and safety of Zygel cannabidiol formulated in a transdermal gel in children and adolescents with Fragile X syndrome FXS. The company said the trial is planned to confirm the positive results observed in a population of responders in its CONNECT-FX trial, a randomized, double-blind, placebo-controlled trial that assessed the efficacy and safety of Zygel as a treatment for the behavioral symptoms of FXS. 